Scholarlink

<p>Radioligand therapy with <sup>177</sup>Lu-Prostate Specific Membrane Antigen is a&#xa0;very promising treatment option for patients with prostate cancer. In the past ten years it started to be used as one of the final options in patients with metastatic, castration resistant prostate cancer, after previously exploiting all the common treatments. In Slovakia, this treatment has been available since the beginning of the year 2020. In this time, we have been able to adopt many of the recommendations from the European guidelines and adapt the rest to the clinical and national legislative requirements. In the time period between February 2020 and June 2024, we treated 104 patients and administered total of 362 cycles of the radioligand therapy with <sup>177</sup>Lu-Prostate Specific Membrane Antigen. Although the numbers of our patients suitable for systemic evaluation are for now rather small, our result has so far showed the correlation with some of the largest multicentric trials. More patients will be included in the further evaluation with upcoming months, and more precise data will be available.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Guide to 177Lu-Prostate Specific Membrane Antigen Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer in Slovakia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月14日

查看全文
  • Andrej Vondrak,
  • Stanislava Bakova,
  • Vladimir Procka,
  • Tomas Pinter,
  • Ondrej Lukac,
  • Alexander Haug,
  • Monika Kmetova-Sivonova,
  • Jana Jurecekova,
  • Hubert Polacek,
  • Daniel Evin,
  • Jan Breza,
  • Dusan Dobrota

摘要

Radioligand therapy with 177Lu-Prostate Specific Membrane Antigen is a very promising treatment option for patients with prostate cancer. In the past ten years it started to be used as one of the final options in patients with metastatic, castration resistant prostate cancer, after previously exploiting all the common treatments. In Slovakia, this treatment has been available since the beginning of the year 2020. In this time, we have been able to adopt many of the recommendations from the European guidelines and adapt the rest to the clinical and national legislative requirements. In the time period between February 2020 and June 2024, we treated 104 patients and administered total of 362 cycles of the radioligand therapy with 177Lu-Prostate Specific Membrane Antigen. Although the numbers of our patients suitable for systemic evaluation are for now rather small, our result has so far showed the correlation with some of the largest multicentric trials. More patients will be included in the further evaluation with upcoming months, and more precise data will be available.